Responsibilities of the team, page-35

I honestly don't think RAC will be the same as the companies I mentioned. Hope these are just extreme examples. If this topic interest to you, read up on Valeant Pharmaceuticals.

Valeant Pharmaceuticals slashed its research budget and focused entirely on buying up other companies’ medicines and then jacking up the prices. In once instance, a vital drug for people with a rare copper allergy went from $30 a month to $20,000 a month. As people handed over their life savings to stay alive, Valeant’s stock price soared. At least the then Valeant CEO (Mike Pearson) was very honest. He said upfront that he is only there to increase value for shareholders.

Once again, I honestly believe the RAC is not in the same category and my examples are of the extreme. However, better to sit at the table and have a say then screaming from the outside.